These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18030130)

  • 1. Periocular cutaneous toxicity and cicatricial ectropion: a potential class effect of antineoplastic agents that inhibit EGFR signaling.
    Frankfort BJ; Garibaldi DC
    Ophthalmic Plast Reconstr Surg; 2007; 23(6):496-7. PubMed ID: 18030130
    [No Abstract]   [Full Text] [Related]  

  • 2. Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab.
    Garibaldi DC; Adler RA
    Ophthalmic Plast Reconstr Surg; 2007; 23(1):62-3. PubMed ID: 17237696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newly recognized ocular side effects of erlotinib.
    Methvin AB; Gausas RE
    Ophthalmic Plast Reconstr Surg; 2007; 23(1):63-5. PubMed ID: 17237697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases.
    Saint-Jean A; Sainz de la Maza M; Morral M; Torras J; Quintana R; Molina JJ; Molina-Prat N
    Ophthalmology; 2012 Sep; 119(9):1798-802. PubMed ID: 22584020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib-related corneal melting.
    Chow VW; Jhanji V; Chi SC
    Ophthalmology; 2013 May; 120(5):1104.e1. PubMed ID: 23642754
    [No Abstract]   [Full Text] [Related]  

  • 6. Author reply: To PMID 22584020.
    Molina-Prat N; Saint-Jean A; Sainz de la Maza M
    Ophthalmology; 2013 May; 120(5):1104-5. PubMed ID: 23642746
    [No Abstract]   [Full Text] [Related]  

  • 7. Epidermal growth factor receptor tyrosine kinase inhibitors and depression.
    Pirl WF; Solis J; Greer J; Sequist L; Temel JS; Lynch TJ
    J Clin Oncol; 2009 Aug; 27(23):e49-50; author reply e51. PubMed ID: 19597022
    [No Abstract]   [Full Text] [Related]  

  • 8. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal dependence of the effect of radiation on erlotinib-induced skin rash.
    Lacouture ME; Hwang C; Marymont MH; Patel J
    J Clin Oncol; 2007 May; 25(15):2140; author reply 2141. PubMed ID: 17513824
    [No Abstract]   [Full Text] [Related]  

  • 11. Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
    Burotto M; Ali SA; O'Sullivan Coyne G
    Expert Opin Drug Saf; 2015 Jan; 14(1):97-110. PubMed ID: 25345687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten lessons from EGFR.
    Nakanishi Y
    Respir Investig; 2014 May; 52(3):151-2. PubMed ID: 24853013
    [No Abstract]   [Full Text] [Related]  

  • 13. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
    Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
    BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cutaneous side effects of EGF receptor inhibitors].
    Nassar D; Soutou B; Aractingi S
    Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.
    Lacouture ME; Melosky BL
    Skin Therapy Lett; 2007; 12(6):1-5. PubMed ID: 17762902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palmar bullous blistering induced by erlotinib.
    Berg A; Brustugun OT; Lund-Iversen M; Helland Å
    J Thorac Oncol; 2011 May; 6(5):954. PubMed ID: 21623268
    [No Abstract]   [Full Text] [Related]  

  • 18. A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.
    Yamada K; Aono H; Hosomi Y; Okamoto H; Kato T; Komase Y; Nishikawa M; Azuma K; Takeoka H; Okuma Y; Nakahara Y; Sato A; Oba MS; Morita S; Kunitoh H; Watanabe K
    Eur J Cancer; 2015 Sep; 51(14):1904-10. PubMed ID: 26174465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
    Santoro F; Cozzani E; Parodi A
    J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trichomegaly secondary to erlotinib.
    Desai RU; Rachakonda LP; Saffra NA
    Can J Ophthalmol; 2009 Dec; 44(6):e65. PubMed ID: 20052001
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.